Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

Washington state’s attorney general alleges the Trump administration has violated a preliminary injunction intended to stop it from cutting research funding.

President Donald Trump’s proposed budget for fiscal year 2026 would reduce the NIH budget by nearly $18 billion.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Experts say the Trump administration's cancellation of more than $800 million in research focused on LGBTQ patients could harm public health.

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.